Structure

InChI Key DADASRPKWOGKCU-FVTQAUBDSA-N
Smile COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@H](C)O[C@H](C)C5)cc4)n[nH]c3c1)C(=O)N2
InChI
InChI=1S/C33H34N4O3/c1-20-17-37(18-21(2)40-20)19-23-6-4-22(5-7-23)8-12-29-26-11-9-24(14-31(26)36-35-29)28-16-33(28)27-15-25(39-3)10-13-30(27)34-32(33)38/h4-15,20-21,28H,16-19H2,1-3H3,(H,34,38)(H,35,36)/b12-8+/t20-,21+,28-,33-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C37H38N4O7
Molecular Weight 650.73
AlogP 5.73
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 6.0
Polar Surface Area 79.48
Molecular species NEUTRAL
Aromatic Rings 4.0
Heavy Atoms 40.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Serine/threonine-protein kinase PLK4 inhibitor PubMed
Primary Target
polo like kinase 4

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Breast Neoplasms 2 D001943 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 2 D064129 ClinicalTrials
Neoplasms 1 D009369 ClinicalTrials

Related Entries

Scaffolds

Cross References

Resources Reference
ChEMBL CHEMBL4297462
FDA SRS 09OB3E5QTD
Guide to Pharmacology 8063
PubChem 91754527
ChEMBL CHEMBL3408947
FDA SRS TL1UD860AA
Guide to Pharmacology 8063
PubChem 91754527
SureChEMBL SCHEMBL9946383
ZINC ZINC000145048061